

pathways in cell culture studies by decreasing oxidant production (12). Above controversies regarding the effect of MB on oxidative stress parameters emerged mainly due to the various systems used to study its effect, the dose and mode of application of the drug used in different studies. However, it is not clear how MB influences oxidative stress in tissues of rats. In the present study, effect of 1 mM MB in drinking water for 30 days was assessed on antioxidants like superoxide dismutase, catalase, and reduced glutathione and oxidant parameter like lipid peroxidation in liver and kidney of adult female rats.

METHODS

Chemicals

Methylene blue was obtained from E. Merck, Germany. Sodium dodecyl sulphate (SDS), Butylated hydroxyl toluene (BHT), Triton-X 100, Hydrogen peroxide (H_2O_2), L-methionine, Hydroxylamine Hydrochloride, N-(1-Naphthylethylene diamine), and Sulfanilamide, 5,5'-Dithiobis-2-nitrobenzoic acid (DTNB) were procured from SRL, India. Thiobarbuturic acid (TBA) and Bovine serum albumin (BSA) were purchased from Sigma Chemical Company, USA. Bradford reagent was obtained from Biogene Reagents Inc. USA. All other chemicals used were of the analytical grade.

Animals and treatments

Ten female adult rats of Wistar strain weighing about 200 g were used in the present experiments. The rats were divided into two groups each having five individuals. Group I served as control, and group II received MB at concentration of 1 mM in drinking water for 30 days. Animal care,

maintenance and experiments were done under the supervision of the Institutional Animal Ethics Committee (IAEC) regulated by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India.

Sample preparation

After recording the body weights rats were sacrificed by decapitation. Trunk blood was collected to obtain serum and the serum was stored at $-20^\circ C$ until measurement of alanine aminotransferase (AlaAT), creatinine and blood urea nitrogen (BUN). Liver and kidney were dissected out immediately, cleaned in cold normal saline and stored at $-80^\circ C$ till further use.

A 10% homogenate of tissues were prepared in ice-cold phosphate buffer (50 mM, pH 7.4). Homogenate was centrifuged at $900 \times g$ for 5 minutes at $4^\circ C$ to separate nuclei and cellular debris and further centrifuged at $10,000 \times g$ for 20 minutes at $4^\circ C$ (13). Lipid peroxidation (14) and reduced glutathione (15) levels were measured in $900 \times g$ supernatant fraction, while the activities of superoxide dismutase (16) and catalase (17) were measured in $10,000 \times g$ supernatant fraction of samples. The activity of AlaAT in serum was determined by standard procedures using commercially available diagnostic laboratory test kit (Merck, India). Concentrations of BUN and creatinine were assessed using diagnostic laboratory test kit (Crest Biosystems, India).

Statistical analysis

Data are expressed as means \pm SD. Students' unpaired *t* test was performed to find level of significance between groups ($P < 0.05$ and $P < 0.001$).

RESULTS

Administration of MB to rats in drinking water for 30 days did not affect activities of two principal antioxidant enzymes SOD and CAT of liver and kidney. Also the treatment failed to influence level of GSH in these organs. Interestingly, lipid peroxidation level of liver was augmented while that of the kidney decreased significantly ($P<0.05$) in response to MB indicating an organ specific effect of the drug. There were no change in the level of serum BUN, but serum concentration of creatinine and AlaAT decreased significantly ($P<0.001$) in MB treated group as compared to the control group (Table I).

TABLE I: Effect of methylene blue (1 mM in drinking water for 30 days) on liver and kidney of rat.

Parameters	Groups	
	Control	MB
Body weight (g)		
Initial	182±9.79	186±6.61
Final	186.2±9.68	181±6.63
Liver		
SOD (U/mg protein)	9.43±0.92	10.22±0.94
CAT (μ kat/mg protein)	6.85±0.31	7.46±0.77
LPx (TBARS/mg protein)	0.66±0.09	0.82±0.08*
GSH (μ mol/g protein)	4.39±0.33	4.64±0.15
Kidney		
SOD (U/mg protein)	10.15±0.82	10.95±0.89
CAT (μ kat/mg protein)	2.95±0.35	2.76±0.113
LPx (TBARS/mg protein)	2.29±0.009	2.07±0.1*
GSH (μ mol/g protein)	2.21±0.51	2.78±0.5
Serum		
AlaAT (U/L)	26.97±3.94	15.66±2.29**
Creatinine(mg/dL)	0.414±0.02	0.313±0.026**
BUN (mg/dL)	19.44±1.51	18.00±0.12

Data were expressed as means±SD. * $P<0.05$; ** $P<0.001$ as compared to controls.

DISCUSSION

MB potentially represents a new class of antioxidant drugs that competitively inhibit the reduction of molecular oxygen to superoxide by acting as an alternative electron acceptor for tissue oxidases (18). It

can accept electrons from pyrimidine nucleotides and transfers them to oxygen non-enzymatically (19) and reduced MB inside the cell can be oxidized by molecular oxygen. It is also oxidized by reduction of Fe^{3+} in prosthetic groups of numerous cellular proteins and enzymes (20) and in due course can generate ROS. MB has been shown to prevent ethanol induced redox changes in isolated hepatocytes and HeLa cells (5, 6) and in rats fed with ethanol for long time (8).

Peter *et al.* (21) have reported that distribution of MB is much higher in liver than other organs after the oral administration of the drug in rats. MB at a concentration more than 5 μ M has been shown to increase intracellular oxidant stress in endothelial cells (11). In liver of rats, MB has been shown to stimulate mitochondrial respiration (22). Therefore, high content of MB in liver and high metabolic activities of liver may be the reason for observed enhanced lipid peroxidation content in the present study. However, at this point, it is difficult to access the mechanism by which MB enhanced liver malondialdehyde content. The dose used in the present study is not hepatotoxic as evident by low serum alaline amino transaminase (AlaAT) activity.

MB is used to treat urolithiasis (23). Oxidative stress is implemented in several kidney pathophysiology including urolithiasis (24) and MB has been reported to protect kidney tissue from oxidative damage induced by Ciclosporin A treatment (10). The decrease in creatinine level in the serum and lipid peroxidation level in the kidney of MB treated rats also supports the above view. However, the activity of antioxidant enzyme SOD and CAT and level of GSH did not show any change after administration of MB for 30 days.

In conclusion, the present investigation indicates that MB has organ specific effect and is better in protecting kidney than liver.

ACKNOWLEDGEMENTS

The first author is thankful to the

Department of Biotechnology (DBT), Government of India, for providing fellowship (Grant letter DBT-JRF/05-06/101) and Department of Biotechnology, Utkal University for laboratory facilities to carry out this study.

REFERENCES

- Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, Kahn RJ, Vincent JL. Methylene blue administration in septic shock: a clinical trial. *Crit Care Med* 1995; 23: 259-264.
- Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. *Eur J Clin Pharmacol* 1996; 50: 249-252.
- Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. *Ann Emerg Med* 1999; 34: 646-656.
- Mayer B, Brunner F, Schimdt K. Novel actions of methylene blue. *Eur Heart J* 1993; 14: (suppl. I), 22-26.
- Cronholm T. Ethanol metabolism in isolated hepatocytes: Effects of methylene blue, cyanamide and penicillamine on the redox state of the bound coenzyme and on the substrate exchange at alcohol dehydrogenase. *Biochem Pharmacol* 1993; 45: 553-558.
- Galli A, Price D, Crabb D. High-level expression of rat class I alcohol dehydrogenase is sufficient for ethanol-induced fat accumulation in transduced HeLa cells. *Hepatology* 1999; 29: 1164-1170.
- Sass MD, Caruso CJ, Axelrod DR. Accumulation of methylene blue by metabolizing erythrocytes. *J Lab Clin Med* 1967; 69: 447-455.
- Vonlanthen R, Beer JH, Lauterburg BH. Effect of methylene blue on the disposition of ethanol. *Alcohol & Alcoholism* 2000; 35: 424-426.
- May, JM, Qu Z, Cobb CE. Reduction and uptake of methylene blue by human erythrocytes. *Amr J Physiol Cell Physiol* 2004; 286: C1390-C1398.
- Rezzani R, Rodella L, Corsetti G, Bianchi R. Does Methylene Blue Protect the Kidney Tissues from Damage Induced by Ciclosporin A Treatment? *Nephron* 2001; 89: 329-336.
- May JM, Qu Z, Cobb CE. Generation of oxidant stress in cultured endothelial cells by methylene blue: protective effects of glucose and ascorbic acid. *Biochem Pharmacol* 2003; 66: 777-784.
- Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, Ames BN. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. *The FASEB J* 2007; fj.07-9610com.
- Das K, Chainy GBN. Modulation of rat liver mitochondrial antioxidant defence system by thyroid hormone. *Biochem Biophys Acta* 2001; 1537: 1-13.
- Das K, Samanta L, Chainy GBN. A modified spectrophotometric assay of superoxide dismutase using nitrite formation by superoxide radicals. *Indian J Biochem Biophys* 2000; 37: 201-204.
- Aebi H. Catalase. In: *Methods in Enzymatic Analysis*, Vol. II, Bergmayer, H.U. (Ed.), Academic Press, New York 1974: 673-678.
- Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxide in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 1979; 95: 351-258.
- Sedlak J, Lindsay RH. Estimation of total, protein-bound and non protein sulfhydryl groups in tissue with Ellman's reagent. *Anal Biochem* 1968; 25: 192-205.
- Salaris SC, Babbs CF, Vorhees WD. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. *Biochem Pharmacol* 1991; 42: 171-174.
- Metz EN, Balcerzak SP, Sagone AL Jr. Mechanisms of methylene blue stimulation of the hexose monophosphate shunt in erythrocytes. *J Clin Invest* 1976; 58: 797-802.
- McCord JM, Fridovich I. The utility of superoxide dismutase in studying free radical reactions. II. The mechanism of mediation of cytochrome c reduction by variety of electron carriers. *J Biol Chem* 1970; 245: 1374-1377.
- Peter C, Hongwan D, Kupfer A, Lauterurg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. *Eur J Clin Pharmacol* 2000; 56: 247-250.
- Visarius TM, Stucki JW, Lauterberg BH. Stimulation of respiration by methylene blue in rat liver mitochondria. *FEBS Lett* 1997; 412: 157-160.
- Smith, MJ. Methylene blue in renal calculi. Results of five year study. *Urology* 1975; 6: 676-679.
- Selvam R, Kalaiselvi P. Studies on calcium oxalate binding proteins: Effect on lipid peroxidation. *Nephron* 2001; 88: 163-167.